ACTRN12610000051044已完成未知
A prospective, randomized, double-blinded, multicentre study to evaluate the benefits of frequent Atrio Ventricular (AV/PV) and Inter-Ventricular (V-V) delay optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibribrillator (CRT-D) Device.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patient meets current CRT-D indications and be implanted with a St. Jude Medical (SJM) CRT-D device with V-V timing and a copatible lead system.
- •- Patient has the ability to complete a 6-minute hall walk with the only limiting factor to be fatigue or shortness of breath
- •-Patient has the ability to independantly comprehend and complete a Quality Of Life (QOL) questionnaire
- •- Patient is geographically stable and willing to coply with the required follow up schedule
排除标准
- •- Patient has an epicardial ventricular lead system
- •-patient has the ability to walk greater or equal to 450 meters in 6 meters
- •- Patient has limited intrinsic atrial activity (<40bpm)
- •- Patient has persistent or permanent Atrial Fibrillation (AF)
- •- Patient has a 2 or 3 degree heart block
- •- Patients life expectancy is less than a year
- •- Patient is less than 18yrs old
- •- Patient is pregnant
- •- Patient is on an Intravenous (IV) inotropic agent
研究者
相似试验
已完成
不适用
To assess the efficacy and safety of an Immunostimulant supplement on the immunity of healthy human subjectsCTRI/2021/07/035206OmniActive Health Technologies30
已完成
不适用
A prospective, randomized, double-blind, multiple dose, parallel, placebo-controlled, clinical interventional study.CTRI/2021/01/030493OmniActive Health Technologies
尚未招募
3 期
A Clinical Study to Assess the Efficacy and Safety of Cetirizine Ophthalmic SolutioCTRI/2024/08/072453AKUMS DRUGS PHARMACEUTICALS LTD
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs Rifamycin SV-MMX® 600 mg b.i.d. three times daily vs placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-ITDr. Falk Pharma GmbH375
进行中（未招募）
1 期
A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs. Rifamycin SV-MMX® 600 mg three times daily vs. placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)EUCTR2012-003300-13-LVDr. Falk Pharma GmbH375